Home Medicine Cinacalcet treatment experience in hereditary vitamin D resistant rickets
Article
Licensed
Unlicensed Requires Authentication

Cinacalcet treatment experience in hereditary vitamin D resistant rickets

  • Jesús Lucas ORCID logo EMAIL logo , Jose Luis Badia , Elena Lucas and Ana Remon
Published/Copyright: January 11, 2020

Abstract

Background

Hereditary vitamin D resistant rickets (HVDRR) is a bone disorder characterized by a phenotype of rickets with onset at early stage of life with elevated alkaline phosphatase, hypocalcemia, hypophosphatemia, hyperparathyroidism and elevated levels of 1,25-dihydroxyvitamin D (calcitriol) as a consequence of the resistance of the vitamin D receptor (VDR). Mutations in the DNA-binding domain of the VDR of the vitamin D receptor have been characterized by a lack of response to traditional treatment with calcium and calcitriol. Secondary hyperparathyroidism and hypophosphatemia are the main factors in its pathogenesis. Cinacalcet is a calciomimetic drug that reproduces the action of calcium by increasing the sensitivity of the calcium-sensitive receptors (CASR) of the parathyroid glands that regulate the secretion of the parathyroid hormone (PTH).

Case presentation

We describe its effectiveness and safety in a patient with HVDRR and review other published report cases in the literature. According to published experience, cinacalcet could be used as an adjunctive treatment for the HVDRR with mutations in the DNA-binding domain of the VDR refractory to traditional treatment. Due to lack of knowledge of possible effects of cinacalcet on CASR in the skeleton, long-term use should be avoided.

Conclusions

The optimal dose of cinacalcet for treatment of HVDRR ranges between 0.25 and 0.5 mg/kg/day. Serious side effects of cinacalcet have not been published in this type of patient, although we considered that a close monitoring is necessary in order to detect hypocalcemia.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: All authors state that they have no conflicts of interest.

  6. Informed consent: Informed consent forms were obtained from the parents of the patients for publication of the cases, including images.

References

1. Brooks MH, Stern PH, Bell NH. Vitamin D-dependent rickets type II. N Engl J Med 1980;302:810.10.1056/NEJM197805042981804Search in Google Scholar PubMed

2. Portale A, Perwad F, Miller W. Rickets due to hereditary abnormalities of vitamin D synthesis or action. In: Glorieux F, Pettifor JM, Juppner H, editors. Pediatric bone, 2nd ed. Oxford: Elsevier, 2012:679–98.10.1016/B978-0-12-382040-2.10025-5Search in Google Scholar

3. Sahay M, Sahay R. Rickets-vitamin D deficiency and dependency. Indian J Endocrinol Metab 2012;16:164–76.10.4103/2230-8210.93732Search in Google Scholar PubMed PubMed Central

4. Marx S, Spiegel A, Brown E, Gardner D, Downs R, et al. A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 1978;47:1303–10.10.1210/jcem-47-6-1303Search in Google Scholar PubMed

5. Srivastava T, Alon US. Cinacalcet as adjunctive therapy for hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Bone Miner Res 2013;28:992–6.10.1002/jbmr.1838Search in Google Scholar PubMed

6. Nemeth EF, Shoback D. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. Best Pract Res Clin Endocrinol Metab 2013;27:373–84.10.1016/j.beem.2013.02.008Search in Google Scholar PubMed

7. Tiosano D, Hochberg Z. Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 2009;27: 392–401.10.1007/s00774-009-0079-1Search in Google Scholar PubMed

8. Balsan S, Garabédian M, Larchet M, Gorski AM, Cournot G, et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986;77:1661–7.10.1172/JCI112483Search in Google Scholar PubMed PubMed Central

9. Akınci A, Dündar I, Kıvılcım M. The effectiveness of cinacalcet as an adjunctive therapy for hereditary 1,25 dihydroxyvitamin D3-resistant rickets. J Clin Res Pediatr Endocrinol 2017;9:172–8.10.4274/jcrpe.3486Search in Google Scholar PubMed PubMed Central

10. Nicolescu R, Lombet J, Cavalier E. Vitamin D-resistant rickets and cinacalcet – one more favorable experience. Front Pediatr 2018;6:376.10.3389/fped.2018.00376Search in Google Scholar PubMed PubMed Central

11. Surender K, Kochar IP, Ahmad A, Kapoor M. Hereditary vitamin D rickets: a case series in a family. J Pediatr Endocrinol Metab 2014;27:1217–22.10.1515/jpem-2013-0448Search in Google Scholar PubMed

Received: 2019-06-10
Accepted: 2019-11-18
Published Online: 2020-01-11
Published in Print: 2020-02-25

©2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Original Articles
  3. Air occlusion in insulin pumps of children and adolescents with type 1 diabetes
  4. Gastrointestinal symptoms in pediatric patients with type 1 diabetes mellitus
  5. Adherence to multiple medications in the TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) cohort: effect of additional medications on adherence to primary diabetes medication
  6. Ghrelin, obestatin and the ghrelin/obestatin ratio as potential mediators for food intake among obese children: a case control study
  7. Association between neck circumference and non-alcoholic fatty liver disease in Mexican children and adolescents with obesity
  8. Comparison between metabolically healthy obesity and metabolically unhealthy obesity by different definitions among Mexican children
  9. Evidence in obese children: contribution of tri-ponderal mass index or body mass index to dyslipidemia, obesity-inflammation, and insulin sensitivity
  10. Prevalence of metabolic syndrome and its associated factors in overweight and obese adolescents
  11. Cortisol secretion pattern in overweight/obese and normal-weight infants: a cross-sectional study
  12. Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity
  13. Relative leptin deficiency in children with severe early-onset obesity (SEOO) – results of the Early-onset Obesity and Leptin – German-Polish Study (EOL-GPS)
  14. Novel associations of serum adropin and lipopolysaccharide-binding protein versus lipid profiles in childhood obesity
  15. The trade-off between the olfactory bulb and eyeball volume in precocious puberty
  16. Gender-based differences in the clustering of metabolic syndrome factors in children and adolescents
  17. Presentation of 14 alkaptonuria patients from Turkey
  18. Assessment of health-related quality of life in Egyptian children and adolescents with congenital adrenal hyperplasia
  19. Case Reports
  20. Familial hypophosphatemic rickets caused by a PHEX gene mutation accompanied by a NPR2 missense mutation
  21. Cinacalcet treatment experience in hereditary vitamin D resistant rickets
  22. Can we effectively predict the occurrence of cerebral edema in children with ketoacidosis in the course of type 1 diabetes? – case report and literature review
Downloaded on 13.3.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2019-0258/html
Scroll to top button